Isomorphic Labs, the London-based AI-first drug design and development company, has raised $2.1 billion in Series B funding to accelerate its evolution from pioneering novel AI models to applying them at scale. The round is led by Thrive Capital and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, significantly expanding the company’s global capital base.
The capital will be used to develop and deploy Isomorphic Labs’ AI drug design engine, known as IsoDDE, and advance its pipeline of therapeutic programs toward the clinic. Funding will also support hiring across AI, engineering, drug design, and clinical talent at the company’s sites in London, Cambridge, Massachusetts, and Lausanne, Switzerland. Isomorphic Labs has built IsoDDE as a unified system capable of working across multiple therapeutic areas and drug modalities, offering what the company describes as predictive fidelity required to navigate novel biological systems with unprecedented accuracy. The company recently published a subset of IsoDDE’s capabilities, highlighting its predictive accuracy and new features that bridge the gap between structure prediction and real-world drug discovery.
Founded in 2021 and led by CEO Sir Demis Hassabis and President Max Jaderberg, Isomorphic Labs reimagines drug discovery as an integrated scientific and engineering discipline with proprietary AI and data at the core. The company maintains strategic partnerships with Novartis, Lilly, and Johnson & Johnson, which it said serve as significant validation of its AI-first approach and the value it brings to the pharmaceutical industry. The Series B marks a pivotal moment for the company, demonstrating that its first-principles approach to drug design positions it to define the future of AI-driven discovery.
Isomorphic Labs said its drug design engine has already proven its worth across internal programs by hitting key milestones and identifying viable candidates with what it describes as unprecedented speed, establishing a repeatable method for designing new medicines across a wide range of diseases. The company’s long-term vision is to apply AI-driven breakthroughs to the most complex biological and medical challenges and address the global burden of disease, a mission its founder described as solving all disease.
KEY QUOTES:
“This funding round is a massive vote of confidence from a diverse group of top-tier international investors in our AI-first approach to drug design and development. Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential. This capital injection allows us to build out our drug design engine at scale, driving us forward in our mission to solve all disease.”
Sir Demis Hassabis, Founder and CEO, Isomorphic Labs
“This milestone is built on the strength of our AI drug design engine, which has already proven its worth across our internal programs by hitting key milestones and identifying viable candidates with unprecedented speed. Our drug design engine works, and it’s giving us a repeatable way to design new medicines for a wide range of diseases, building a future of medicine that was previously out of reach.”
Max Jaderberg, President, Isomorphic Labs
“The application of AI in healthcare offers a profound opportunity. Isomorphic Labs has already made extraordinary progress in harnessing AI to accelerate drug discovery, and we are excited by this momentum and the early promise of the technology platform. This trajectory is encouraging, and this funding will be used to accelerate the work and bring important interventions to market with greater speed.”
Ruth Porat, President and Chief Investment Officer, Alphabet and Google
“We are humbled to have the opportunity to continue to support Isomorphic’s mission to solve all disease. Over the past year, our conviction in the team has only deepened as they’ve made significant progress in building a unified AI drug design engine to define a new age of drug discovery and design.”
Joshua Kushner, Founder and CEO, Thrive Capital
“The caliber of the team Isomorphic has assembled is unmatched, and they continue to validate our belief that this is the premier group at the intersection of AI and drug discovery. We believe their approach can create important medicines that will be better understood earlier in the process, pushing the boundaries of what’s been possible before.”
Dr. Krishna Yeshwant, Managing Partner, GV
